Sharpepoint LLC Takes Position in Eli Lilly and Company $LLY

Sharpepoint LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,784 shares of the company’s stock, valued at approximately $8,365,000. Eli Lilly and Company accounts for about 5.0% of Sharpepoint LLC’s investment portfolio, making the stock its biggest position.

A number of other large investors have also recently made changes to their positions in the stock. Johnson Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $253,000. Wellspring Financial Advisors LLC boosted its stake in shares of Eli Lilly and Company by 287.5% during the fourth quarter. Wellspring Financial Advisors LLC now owns 2,333 shares of the company’s stock valued at $2,509,000 after purchasing an additional 1,731 shares during the period. Zions Bancorporation National Association UT boosted its stake in shares of Eli Lilly and Company by 10.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 6,018 shares of the company’s stock valued at $6,467,000 after purchasing an additional 557 shares during the period. J.Safra Asset Management Corp boosted its stake in shares of Eli Lilly and Company by 95.9% during the fourth quarter. J.Safra Asset Management Corp now owns 5,310 shares of the company’s stock valued at $5,706,000 after purchasing an additional 2,599 shares during the period. Finally, GWN Securities Inc. lifted its stake in Eli Lilly and Company by 7.6% in the fourth quarter. GWN Securities Inc. now owns 5,221 shares of the company’s stock worth $5,612,000 after acquiring an additional 368 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,138.78 on Thursday. The company has a market capitalization of $1.07 trillion, a PE ratio of 40.45, a P/E/G ratio of 1.25 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a 50-day simple moving average of $989.96 and a two-hundred day simple moving average of $1,015.14. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were issued a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, Leerink Partners set a $1,119.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,227.74.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA approved extended every-8-weeks maintenance dosing for EBGLYSS, improving convenience and potentially boosting adoption in Lilly’s dermatology business.
• Positive Sentiment: Reuters reported that Lilly is still viewed as the leader in the fast-growing obesity-drug market, even as rivals rush into the space, reinforcing confidence in its competitive moat. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Recent coverage also highlighted positive Phase 3 data for retatrutide and favorable Foundayo (orforglipron) weight-loss results, keeping investor enthusiasm high around Lilly’s obesity pipeline.
• Positive Sentiment: Jefferies raised its price target on LLY to $1,350 and reiterated a Buy rating, signaling continued analyst confidence in the stock’s runway. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Positive Sentiment: Lilly also announced a new Alzheimer’s collaboration with AlzeCure, expanding its neuroscience pipeline and adding another potential long-term growth opportunity.
• Neutral Sentiment: Several articles were commentary pieces or portfolio lists that reinforce Lilly’s reputation as a high-quality defensive growth name, but they do not add materially new fundamental information.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.